Stephen Sims, MD
Pain Medicine · Huntsville, TXNPI 1083623136
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $13,622 of the $19,983 with a category attached, or 68.2%. 46 manufacturers reported payments, led by Abbott at 52.4% of the total. Reporting peaked in 2021 at $4,748 and has fallen 54.7% since, to $2,152 in 2025.
Across 550 payments — averaging $36.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$10K
- MML US, Inc.$2K
- AbbVie$1K
- Boston Scientific$1K
- Medtronic$575
- Relievant Medsystems, Inc.$543
- plus $4K from 40 others
Across 16 payments — averaging $53.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertiflex, Inc.$850
What the payments were for
- Consulting fees$4,98825%
- Travel & lodging$1,3697%
- Food & beverage$13,62268%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$4,869
- Axium Sheath Braided DRG$1,860
- ReActiv8$1,703
- Proclaim Family of SCS IPGs$571
- Proclaim IPG$453
- Intracept$279
- SUPERION$239
- V-LOC 180$146
- Rivacor 7 DR-T$128
- Acticor 7 VR-T DX$128
- BioMonitor$128
- Edora 8 DR-T$128
- MYOBLOC$125
- QULIPTA$125
- UBRELVY$125
- Superion Indirect Decompression System$111
- KYPHON EXPRESS II KYPHOPAK TRAY$111
How this compares
$19,983 in reported general payments places this provider in the 85th percentile of 583 pain medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 77 | $64,603 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 2,416 | $54,972 |
| OxycontinOxycodone Hcl | 16 | $19,246 |
| Fentanyl | 169 | $15,320 |
| QuliptaAtogepant | 13 | $13,753 |
| BelbucaBuprenorphine Hcl | 15 | $10,821 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 350 | $8,916 |
| Gabapentin | 511 | $6,479 |
| MovantikNaloxegol Oxalate | 16 | $6,471 |
| Oxycodone Hcl | 292 | $5,373 |
| Buprenorphine | 15 | $4,886 |
| Pregabalin | 265 | $4,284 |
| Buprenorphine Hcl | 105 | $3,812 |
| Methadone Hcl | 159 | $3,614 |
| Morphine Sulfate ErMorphine Sulfate | 115 | $3,318 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca | $240 | $75,42492 claims |
| AbbVieQulipta | $1,335 | $13,75313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 583 pain medicine providers in Texas.
Other pain medicine in Huntsville
- Anisa GopalaniHuntsville$35K
- Melissa MurphyGrapevine$653K
- Shiraz YazdaniLubbock$514K
- Aaron CalodneyTyler$296K
- Candice BurnetteSugar Land$265K
- Ashley Bailey-ClassenFort Worth$244K
- Grant ChenHouston$175K
- Gunjan PatelHouston$166K
- Anthony BergRockwall$165K
- Puneet SayalCorpus Christi$153K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.